18F-Labeled Prosthetic Group for Mild-Condition Biomolecule Labeling

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Traditional methods for labeling biological molecules with 18F are challenging due to harsh conditions required, such as high temperatures and organic solvents, leading to instability and inefficiency in producing radiotracer compositions for PET imaging.

Innovation Solution

Development of an 18F-labeled prosthetic group containing a nitro-pyridine linked to a polyethylene glycol (PEG) moiety and a terminal azide, which is water-soluble and less volatile, enabling efficient and rapid labeling of biomolecules through bioorthogonal 'click' reactions, maintaining biological activity and allowing for UV monitoring of radiochemical purity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If traditional 18F-labeling methods are used with harsh conditions (high temperatures, organic solvents, strong basic conditions), then the labeling reaction can proceed, but the biological activity of the biomolecule is compromised and the process becomes inefficient

Engineering Contradiction:
Improvelabeling process feasibilityVSAvoidbiomolecule biological activity
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The invention changes the reaction parameters from harsh conditions (high temperature, organic solvents, strong base) to mild aqueous conditions (room temperature or physiological temperature, water-based solvent, neutral or weakly basic pH). This allows the labeling reaction to proceed while preserving the biological activity of the biomolecule.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention introduces a prosthetic group as an intermediary molecule that contains both the 18F-labeling moiety and a bioorthogonal functional group (such as azide or alkyne). This intermediary enables the labeling reaction to occur under mild conditions through bioorthogonal chemistry, protecting the biomolecule from harsh conditions.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Productivity

If rapid labeling is achieved through streamlined processes, then productivity increases, but measurement and monitoring of radiochemical purity becomes more difficult

Engineering Contradiction:
Improvelabeling speedVSAvoidradiochemical purity monitoring
Core Design Contradiction:
ProductivityVSDifficulty of detecting and measuring

Solution Approach 1:

The prosthetic group is designed to contain a chromophore (such as a pyridine ring with characteristic UV absorbance) that allows monitoring of the labeling reaction and purification process by UV spectroscopy. This enables rapid assessment of radiochemical purity without complex analytical methods.

Inventive Principle:
Principle #32Color changes

3Productivity

If highly reactive 18F-labeling reagents are used to increase reaction speed, then productivity improves, but volatility and loss of radioactive material increase

Engineering Contradiction:
Improvereaction rateVSAvoidradioactive material loss
Core Design Contradiction:
ProductivityVSLoss of substance

Solution Approach 1:

The invention creates a composite prosthetic group molecule that combines the 18F-labeling functionality with a stable, non-volatile molecular framework (such as a pyridine ring connected to a PEG chain). This composite structure maintains high reactivity for rapid labeling while eliminating volatility and reducing radioactive material loss.

Inventive Principle:
Principle #40Composite materials

Data Source

PatentUS11806409B2Imaging methods using 18F-radiolabeled biologics
Publication Date: 2023.11.07 BRISTOL MYERS SQUIBB CO
  • US11806409B2 patent drawing
  • US11806409B2 patent drawing
  • US11806409B2 patent drawing

AI summary

The invention relates to water soluble 18F-prosthetic groups and the synthesis and use of 18F-labeled biological molecules containing the 18F-prosthetic groups for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.